(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Praxis Precision Medicines's revenue in 2026 is $0.On average, 19 Wall Street analysts forecast PRAX's revenue for 2026 to be $107,086,453, with the lowest PRAX revenue forecast at $0, and the highest PRAX revenue forecast at $355,014,568. On average, 18 Wall Street analysts forecast PRAX's revenue for 2027 to be $8,415,129,191, with the lowest PRAX revenue forecast at $2,650,285,268, and the highest PRAX revenue forecast at $18,460,646,146.
In 2028, PRAX is forecast to generate $30,190,302,972 in revenue, with the lowest revenue forecast at $10,656,007,214 and the highest revenue forecast at $60,575,561,775.